Cwm LLC Makes New Investment in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)

Cwm LLC acquired a new position in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,400 shares of the company’s stock, valued at approximately $44,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SBIO. Raymond James Financial Services Advisors Inc. increased its holdings in ALPS Medical Breakthroughs ETF by 32.2% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 27,763 shares of the company’s stock valued at $934,000 after purchasing an additional 6,757 shares during the period. Flow Traders U.S. LLC increased its stake in shares of ALPS Medical Breakthroughs ETF by 69.4% during the first quarter. Flow Traders U.S. LLC now owns 15,594 shares of the company’s stock valued at $525,000 after buying an additional 6,390 shares during the period. Captrust Financial Advisors increased its stake in shares of ALPS Medical Breakthroughs ETF by 903.6% during the first quarter. Captrust Financial Advisors now owns 1,666 shares of the company’s stock valued at $56,000 after buying an additional 1,500 shares during the period. Royal Bank of Canada grew its holdings in shares of ALPS Medical Breakthroughs ETF by 16.3% during the 1st quarter. Royal Bank of Canada now owns 41,874 shares of the company’s stock worth $1,408,000 after acquiring an additional 5,854 shares during the period. Finally, Beacon Pointe Advisors LLC grew its holdings in shares of ALPS Medical Breakthroughs ETF by 18.9% during the 1st quarter. Beacon Pointe Advisors LLC now owns 31,411 shares of the company’s stock worth $1,057,000 after acquiring an additional 5,000 shares during the period.

ALPS Medical Breakthroughs ETF Trading Up 0.7 %

SBIO stock opened at $23.81 on Monday. ALPS Medical Breakthroughs ETF has a fifty-two week low of $23.41 and a fifty-two week high of $33.82. The business’s 50 day moving average price is $26.60 and its two-hundred day moving average price is $29.72.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.